Repeated use of hybrid isolated chemoperfusion with melphalan in non-resectable liver malignancy
A. I. Babich,
M. A. Privalov,
A. E. Demko,
V. A. Reva,
V. A. Manukovskiy,
V. V. Cheremisov,
I. V. Reshetov https://doi.org/10.21294/1814-4861-2024-23-1-155-161
Abstract
Background. The incidence of liver malignancies is increasing, radical surgery can be performed in a small number of patients, most of them receive drug treatment. Isolated liver chemoperfusion (ILP) is a method of regional chemotherapy that is effective for some metastases but has a high complexity and frequency of complications. An improved method of hybrid ILP may offer new opportunities for patients with unresectable liver tumors. Case report. A 64-year-old patient diagnosed with stage IV sigmoid colon cancer underwent hybrid ILP. The patient was discharged after 6 days in a satisfactory condition without complications. Systemic chemotherapy was performed 21 days after the first hybrid chemoperfusion. The second hybrid chemoperfusion procedure was performed without the laparotomy stage, mobilizing the right common femoral vein and artery. As a result of the chemotherapy, the patients received a positive result on the mRECIST scale – a complete tumor response. Conclusion. The developed method of hybrid ILP has several advantages over traditional ILP and chemosaturation with infusion into the hepatic artery. This method can also be performed repeatedly, which is not possible with traditional ILP.
About the Authors
A. I. Babich
Saint Petersburg Research Institute named after I.I. Dzhanelidze
Russian Federation
Russian Federation
Alexander I. Babich - MD, DSc, Senior Researcher, Saint Petersburg Research Institute named after I.I. Dzhanelidze.
3, lit. A, Budapest St., Saint Petersburg, 192242
Author ID (Scopus): 57220602346
M. A. Privalov
I.M. Sechenov First Moscow State Medical University of the Ministry of Health of Russia
Russian Federation
Russian Federation
Maxim A. Privalov - Student, N.V. Sklifosovsky Institute of Clinical Medicine, I.M. Sechenov First Moscow State Medical University of the Ministry of Health of Russia.
8/2, Trubetskaya St., Moscow, 119991
Researcher ID (WOS): HSG-4293-2023. Author ID (Scopus): 58608967400
A. E. Demko
Saint Petersburg Research Institute named after I.I. Dzhanelidze
Russian Federation
Russian Federation
Andrey E. Demko - MD, Professor, Deputy Director for Scientific Work, Saint Petersburg Research Institute named after I.I. Dzhanelidze.
3, lit. A, Budapest St., Saint Petersburg, 192242
Researcher ID (WOS): ACM-4880-2022. Author ID (Scopus): 6602311430
V. A. Reva
Saint Petersburg Research Institute named after I.I. Dzhanelidze
Russian Federation
Russian Federation
Viktor A. Reva - MD, DSc, Lecturer, Saint Petersburg Research Institute named after I.I. Dzhanelidze.
3, lit. A, Budapest St., Saint Petersburg, 192242
Researcher ID (WOS): R-4746-2016. Author ID (Scopus): 37004638600
V. A. Manukovskiy
Saint Petersburg Research Institute named after I.I. Dzhanelidze
Russian Federation
Russian Federation
Vadim A. Manukovskiy - MD, Professor, Director, Saint Petersburg Research Institute named after I.I. Dzhanelidze.
3, lit. A, Budapest St., Saint Petersburg, 192242
Researcher ID (WOS): С-9762-2018. Author ID (Scopus): 57216418784
V. V. Cheremisov
I.M. Sechenov First Moscow State Medical University of the Ministry of Health of Russia
Russian Federation
Russian Federation
Vadim V. Cheremisov - MD, PhD, Associate Professor, Department of Oncology, Radiotherapy and Reconstructive Surgery, Head of the Oncology Department of Surgical Methods of Treatment, I.M. Sechenov First Moscow State Medical University of the Ministry of Health of Russia.
8/2, Trubetskaya St., Moscow, 119991
Researcher ID (WOS): X-7838-2019. Author ID (Scopus): 56626538400
I. V. Reshetov
I.M. Sechenov First Moscow State Medical University of the Ministry of Health of Russia
Russian Federation
Russian Federation
Igor V. Reshetov - MD, Professor, Academician of the Russian Academy of Sciences, Director, Institute of Cluster Oncology named after Professor L.L. Levshin, Head of the Department of Oncology, Radiotherapy and Reconstructive Surgery, I.M. Sechenov First Moscow State Medical University of the Ministry of Health of Russia.
8/2, Trubetskaya St., Moscow, 119991
Researcher ID (WOS): J-7005-2014. Author ID (Scopus): 6701353127
References
1. Polikarpov A.A., Tarazov P.G., Granov D.A., Polysalov V.N. X-ray endovascular procedures in the treatment of patients with unresectable liver metastases of colorectal cancer. Russian Journal of Oncology. 2014; 19(4): 40–1. (in Russian).
2. Adam R., Kitano Y. Multidisciplinary approach of liver metastases from colorectal cancer. Ann Gastroenterol Surg. 2019; 3(1): 50–6. doi: 10.1002/ags3.12227.
3. Tzeng C., Aloia T. Colorectal Liver Metastases. J Gastrointest Surg. 2012; 17: 195–201. doi: 10.1007/s11605-012-2022-3.
4. Gruber-Rouh T., Naguib N., Eichler K., Ackermann H., Zangos S., Trojan J., Beeres M., Harth M., Schulz B., Nour-Eldin A., Vogl T.J. Transarterial chemoembolization of unresectable systemic chemotherapy-refractory liver metastases from colorectal cancer: Long-term results over a 10-year period. Int J Cancer. 2013; 134: 1225–31. doi: 10.1002/ijc.28443.
5. Alexander H.R., Bartlett D.L., Libutti S.K., Pingpank J.F., Fraker D.L., Royal R., Steinberg S.M., Helsabeck C.B., Beresneva T.H. Analysis of factors associated with outcome in patients undergoing isolated hepatic perfusion for unresectable liver metastases from colorectal center. Ann Surg Oncol. 2009; 16(7): 1852–9. doi: 10.1245/s10434-009-0482-9.
6. Ben-Shabat I., Hansson C.,Eilard M., Cahlin C., Rizell M., Lindnér P., Mattsson J., Bagge R. Isolated hepatic perfusion as a treatment for liver metastases of uveal melanoma. J Vis Exp. 2015; (95): 52490. doi: 10.3791/52490.
7. van Iersel L.B.J., Koopman M., van de Velde C.J.H., Mol L., van Persijn van Meerten E.L., Hartgrink H.H., Kuppen P.J.K., Vahrmeijer A.L., Nortier J.W.R., Tollenaar R.A.E.M., Punt C., Gelderblom H. Management of isolated nonresectable liver metastases in colorectal cancer patients: a case-control study of isolated hepatic perfusion with melphalan versus systemic chemotherapy. Ann Oncol. 2010; 21(8): 1662–7. doi: 10.1093/annonc/mdp589.
8. Hafström L.R., Holmberg S.B., Naredi P.L., Lindnér P.G., Bengtsson A., Tidebrant G., Scherstén T.S. Isolated hyperthermic liver perfusion with chemotherapy for liver malignancy. Surg Oncol. 1994; 3(2): 103–8. doi: 10.1016/0960-7404(94)90005-1.
9. Huibers A., DePalo D.K., Perez M.C., Zager J.S., Olofsson Bagge R. Isolated hyperthermic perfusions for cutaneous melanoma in-transit metastasis of the limb and uveal melanoma metastasis to the liver. Clin Exp Metastasis. 2023. doi: 10.1007/s10585-023-10234-6.
10. Olofsson Bagge R., Nelson A., Shafazand A., All-Eriksson C., Cahlin C., Elander N., Helgadottir H., Kiilgaard J.F., Kinhult S., Ljuslinder I., Mattsson J., Rizell M., Sternby Eilard M., Ullenhag G.J., Nilsson J.A., Ny L., Lindnér P. Isolated Hepatic Perfusion With Melphalan for Patients With Isolated Uveal Melanoma Liver Metastases: A Multicenter, Randomized, Open-Label, Phase III Trial (the SCANDIUM Trial). J Clin Oncol. 2023; 41(16): 3042–50. doi: 10.1200/JCO.22.01705.
11. Bethlehem M.S., Katsarelias D., Olofsson Bagge R. Meta-Analysis of Isolated Hepatic Perfusion and Percutaneous Hepatic Perfusion as a Treatment for Uveal Melanoma Liver Metastases. Cancers (Basel). 2021; 13(18): 4726. doi: 10.3390/cancers13184726.
12. Eggermont A.M., van IJken M.G., van Etten B., van der Sijp J.R., ten Hagen T.L., Wiggers T., Oudkerk M., de Boeck G., de Bruijn E.A. Isolated hypoxic hepatic perfusion (IHHP) using balloon catheter techniques: from laboratory to the clinic towards a percutaneous procedure. Hepatogastroenterology. 2000; 47(33): 776–81.
13. Dewald C.L.A., Becker L.S., Maschke S.K., Meine T.C., Alten T.A., Kirstein M.M., Vogel A., Wacker F.K., Meyer B.C., Hinrichs J.B. Percutaneous isolated hepatic perfusion (chemosaturation) with melphalan following right hemihepatectomy in patients with cholangiocarcinoma and metastatic uveal melanoma: peri- and post-interventional adverse events and therapy response compared to a matched group without prior liver surgery. Clin Exp Metastasis. 2020; 37(6): 683–92. doi: 10.1007/s10585-020-10057-9.
14. Vogel A., Ochsenreither S., Zager J.S., Wacker F., Saborowski A. Chemosaturation for primary and secondary liver malignancies: A comprehensive update of current evidence. Cancer Treat Rev. 2023; 113: 102501. doi: 10.1016/j.ctrv.2022.102501.
15. Rowcroft A., Loveday B.P.T., Thomson B.N.J., Banting S., Knowles B. Systematic review of liver directed therapy for uveal melanoma hepatic metastases. HPB (Oxford). 2020; 22(4): 497–505. doi: 10.1016/j.hpb.2019.11.002.
Review
For citations:
Babich A.I., Privalov M.A., Demko A.E., Reva V.A., Manukovskiy V.A., Cheremisov V.V., Reshetov I.V. Repeated use of hybrid isolated chemoperfusion with melphalan in non-resectable liver malignancy. Siberian journal of oncology. 2024;23(1):155-161. (In Russ.) https://doi.org/10.21294/1814-4861-2024-23-1-155-161
Views:
558
Email this article 
